Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.
Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.
Adams
V R
VR
College of Pharmacy, University of Kentucky, Lexington, USA.
Brenner
T
T
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects*; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*
D000970:Antineoplastic Agents; D017370:Interleukin-11; D011994:Recombinant Proteins; C105308:oprelvekin